(Q37789491)

23 August 2017

0 references

Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis (English)

1 reference

23 August 2017

Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis (English)

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

14 July 2024

1 reference

1 reference

1 reference

Apostolos I. Hatzitolios

5

object named as

Apostolos Hatzitolios

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20846651

14 July 2024

author name string

George Ntaios

1

1 reference

23 August 2017

Christos Savopoulos

2

1 reference

23 August 2017

Stavros Chatzopoulos

3

1 reference

23 August 2017

Dimitri Mikhailidis

4

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20846651

14 July 2024

publication date

19 August 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0021915010006842?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

https://api.elsevier.com/content/article/PII:S0021915010006842?httpAccept=text/plain

14 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

14 July 2024

1 reference

23 August 2017

volume

214

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

11-19

1 reference

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Low-Dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial

14 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Folic acid improves arterial endothelial function in adults with hyperhomocystinemia.

14 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial.

14 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction.

14 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins

14 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial

14 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

14 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine lowering and cardiovascular events after acute myocardial infarction

14 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

14 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

14 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial

14 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial

14 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Lowering homocysteine with B vitamins in patients with coronary artery disease

14 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

14 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies

14 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Beta blocker effects on plasma homocysteine levels in patients with hypertension.

14 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease.

14 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus

14 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of a beta-blocker and spironolactone on plasma homocysteine levels.

14 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension

14 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease

14 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension.

14 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study

14 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.

14 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Antihypertensive treatment and homocysteine concentrations

14 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

14 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

14 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Lipid-lowering drugs and homocysteine

14 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

14 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

14 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

14 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia

14 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine elevation with fibrates: is it a class effect?

14 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

14 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Lipid-lowering drugs and homocysteine

14 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease

14 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

14 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.

14 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.

14 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

14 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

14 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes

14 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects

14 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.

14 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus

14 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of fenofibrate and gemfibrozil on plasma homocysteine

14 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Implication of fibrate therapy for homocysteine

14 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

14 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial

14 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia

14 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients.

14 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study

14 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia

14 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study

14 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

14 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia

14 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)

14 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients

14 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?

14 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Statins and homocysteine.

14 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Ant

14 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis

14 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy.

14 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients.

14 July 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

On evolutionary biology, inflammation, infection, and the causes of atherosclerosis

14 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients

14 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia

14 July 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The effect of hormone replacement therapy and simvastatin on plasma homocysteine

14 July 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration

14 July 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial

14 July 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

14 July 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Niacin treatment increases plasma homocyst(e)ine levels

14 July 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production

14 July 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia

14 July 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

14 July 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial

14 July 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.

14 July 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome

14 July 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

14 July 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin

14 July 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial

14 July 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome

14 July 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.

14 July 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome

14 July 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.

14 July 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome

14 July 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes

14 July 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.

14 July 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of short‐term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo‐controlled trial

14 July 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome

14 July 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects

14 July 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine, adrenergic activity and left ventricular mass in patients with essential hypertension

14 July 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

beta-Adrenergic stimulation promotes homocysteic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission.

14 July 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events

14 July 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women

14 July 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients

14 July 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study

14 July 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin

14 July 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The controversial role of B-vitamins in cardiovascular risk: An update.

14 July 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Decrease in serum protein carbonyl groups concentration and maintained hyperhomocysteinemia in patients undergoing bariatric surgery

14 July 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Metabolic syndrome: a solution in search of a problem

14 July 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.

14 July 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study

14 July 2024

112

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

14 July 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Vitamins and stroke: the homocysteine hypothesis still in doubt.

14 July 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?

14 July 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels.

14 July 2024

116

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides

14 July 2024

117

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

Definitions of metabolic syndrome: Where are we now?

14 July 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions

14 July 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.ATHEROSCLEROSIS.2010.08.045

14 July 2024

Identifiers

1 reference

23 August 2017

1 reference